Asthma Endotypes: Mechanisms and Consequences for Airway Epithelium and Mucus

哮喘内型:气道上皮和粘液的机制和后果

基本信息

  • 批准号:
    10371127
  • 负责人:
  • 金额:
    $ 179.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-08 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on recognized clinical risk factors (age and co-morbidities). The biological underpinnings of this clinical variability are unknown but likely relate to variation in both the virus and the host response. A detailed understanding of the risk factors for severe disease, including genetic and environmental factors and the nature of the host immunological response, is essential for the development of prognostic biomarkers and effective therapies. To meet this urgent need we propose to help develop and to participate in the IMPACC multi-center longitudinal clinical study of hospitalized patients with COVID-19 and to immunophenotype participants using shared immunological methods that will be designed an carried out by core laboratories at UCSF and at other participating institutions. Our specific aims are 1) to develop a prospective observational convenience cohort of adult subjects hospitalized with known or presumptive COVID-19, 2) to use this cohort to describe the relationship between specific immunologic assessments and clinical course of COVID-19 in hospitalized patients, and 3) to implement three core laboratories at UCSF to support immunophenotyping in this multicenter cohort. These core laboratories will perform bulk RNA sequencing of blood peripheral blood mononuclear cells (PBMC), bulk metagenomic next-generation sequencing (mNGS) on endotracheal aspirate samples, and serologic phage display assays (PhIP-Seq). Successful completion of these aims will yield critical information regarding the relationship between viral load, host immunological responses, and poor clinical outcomes that are urgently needed for biomarker development and rational therapeutic targeting. In addition, the cellular samples banked in this study may directly contribute to the development of neutralizing antibodies and vaccine strategies that will be our ultimate defense against recurrence of this extraordinary pandemic. A rapid and robust scientific and medical response of the type proposed by the NIAID and the academic community in this consortium is an essential element of a broad response required to protect the health and well-being of all individuals, our health care system, and the broader social structures that maintain global health and welfare.
项目总结/摘要 COVID-19是由新型病毒SARS-CoV-2引起的大流行性疾病,是一种严重的呼吸道疾病, 具有高传染性,根据潜在的风险因素,死亡率从<1%到高达20%不等。 事实上,疾病的严重程度根据公认的临床风险因素(年龄和合并症)而明显不同。 这种临床变异性的生物学基础尚不清楚,但可能与病毒的变异有关。 和宿主的反应。详细了解严重疾病的风险因素,包括遗传和 环境因素和宿主免疫反应的性质,对发展至关重要。 预后生物标志物和有效治疗。为了满足这一迫切需要,我们建议帮助发展和 参与IMPACC多中心COVID-19住院患者纵向临床研究, 免疫表型参与者使用共享的免疫学方法,将由 在UCSF和其他参与机构的核心实验室。我们的具体目标是:(1)发展一个 因已知或推定的疾病住院的成人受试者的前瞻性观察便利队列 COVID-19,2)使用该队列描述特异性免疫学评估与 住院患者的COVID-19临床过程,以及3)在UCSF实施三个核心实验室, 支持本多中心队列的免疫表型分析。这些核心实验室将进行批量RNA 血液外周血单核细胞(PBMC)测序,下一代批量宏基因组 气管内抽吸物样品的测序(mNGS)和血清学噬菌体展示测定(PhIP-Seq)。 成功完成这些目标将产生关于病毒载量, 宿主免疫反应和临床结果差,迫切需要生物标志物 开发和合理的治疗靶向。此外,本研究中储存的细胞样本可能 直接有助于开发中和抗体和疫苗策略,这将是我们最终的目标。 防止这种特殊的流行病再次发生。迅速而有力的科学和医学反应 由NIAID和该联盟中的学术界提出的类型是一个基本要素, 保护所有人的健康和福祉,我们的医疗保健系统, 维护全球健康和福利的更广泛的社会结构。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David J Erle其他文献

Differential gene expression by integrin β7+ and β7- memory T helper cells
  • DOI:
    10.1186/1471-2172-5-13
  • 发表时间:
    2004-07-05
  • 期刊:
  • 影响因子:
    2.700
  • 作者:
    Madeleine W Rodriguez;Agnés C Paquet;Yee Hwa Yang;David J Erle
  • 通讯作者:
    David J Erle

David J Erle的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David J Erle', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10371122
  • 财政年份:
    2020
  • 资助金额:
    $ 179.79万
  • 项目类别:
Understanding Asthma Endotypes
了解哮喘内型
  • 批准号:
    10165891
  • 财政年份:
    2020
  • 资助金额:
    $ 179.79万
  • 项目类别:
Understanding Asthma Endotypes
了解哮喘内型
  • 批准号:
    10165887
  • 财政年份:
    2020
  • 资助金额:
    $ 179.79万
  • 项目类别:
Airway epithelial cell gene regulation: new mechanisms and therapeutic strategies
气道上皮细胞基因调控:新机制和治疗策略
  • 批准号:
    10586412
  • 财政年份:
    2019
  • 资助金额:
    $ 179.79万
  • 项目类别:
Airway epithelial cell gene regulation: new mechanisms and therapeutic strategies
气道上皮细胞基因调控:新机制和治疗策略
  • 批准号:
    10579268
  • 财政年份:
    2019
  • 资助金额:
    $ 179.79万
  • 项目类别:
Airway epithelial cell gene regulation: new mechanisms and therapeutic strategies
气道上皮细胞基因调控:新机制和治疗策略
  • 批准号:
    9915971
  • 财政年份:
    2019
  • 资助金额:
    $ 179.79万
  • 项目类别:
Airway epithelial cell gene regulation: new mechanisms and therapeutic strategies
气道上皮细胞基因调控:新机制和治疗策略
  • 批准号:
    10349455
  • 财政年份:
    2019
  • 资助金额:
    $ 179.79万
  • 项目类别:
Defining A Comprehensive Reference Profile of Circulating Human Extracellular RNA
定义循环人类细胞外 RNA 的综合参考谱
  • 批准号:
    8775079
  • 财政年份:
    2014
  • 资助金额:
    $ 179.79万
  • 项目类别:
Massively parallel identification of functional 3' UTR variants in asthma
哮喘功能性 3 UTR 变异的大规模并行鉴定
  • 批准号:
    8901295
  • 财政年份:
    2014
  • 资助金额:
    $ 179.79万
  • 项目类别:
Defining A Comprehensive Reference Profile of Circulating Human Extracellular RNA
定义循环人类细胞外 RNA 的综合参考谱
  • 批准号:
    9449991
  • 财政年份:
    2014
  • 资助金额:
    $ 179.79万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 179.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了